Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates

AIM: Surgery is an important therapeutic option for Crohn's disease. The need for first bowel surgery seems to have decreased with the introduction of tumour necrosis factor inhibitors (TNFi; adalimumab or infliximab). However, the impact of TNFi on the need for intestinal surgery in Crohn'...

Descripción completa

Detalles Bibliográficos
Autores principales: Eberhardson, Michael, Myrelid, Pär, Söderling, Jonas K., Ekbom, Anders, Everhov, Åsa H., Hedin, Charlotte R. H., Neovius, Martin, Ludvigsson, Jonas F., Olén, Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306633/
https://www.ncbi.nlm.nih.gov/pubmed/34905282
http://dx.doi.org/10.1111/codi.16021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306633/
https://www.ncbi.nlm.nih.gov/pubmed/34905282
http://dx.doi.org/10.1111/codi.16021

Ejemplares similares